66096-722 NDC - LYME DISEASE SUPPORT 1 (ALUMEN, CALCAREA CARBONICA, DNA, FERRUM PHOSPHORICUM, HEPAR SULPHURIS CALCAREUM, KALI CARBONICUM, KALI MURIATICUM, KALI SULPHURICUM, MAGNESIA PHOSPHORICA, NATRUM MURIATICUM, NATRUM PHOSPHORICUM, RNA, SILICEA.)

Drug Information

Product NDC: 66096-722

Proprietary Name: Lyme Disease Support 1

Non Proprietary Name: Alumen, Calcarea carbonica, DNA, Ferrum phosphoricum, Hepar sulphuris calcareum, Kali carbonicum, Kali muriaticum, Kali sulphuricum, Magnesia phosphorica, Natrum muriaticum, Natrum phosphoricum, RNA, Silicea.

Active Ingredient(s):
  • 6 [hp_X]/59mL CALCIUM SULFIDE;
  • 6 [hp_X]/59mL FERROSOFERRIC PHOSPHATE;
  • 4 [hp_C]/59mL HERRING SPERM DNA;
  • 6 [hp_X]/59mL MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE;
  • 6 [hp_X]/59mL OYSTER SHELL CALCIUM CARBONATE, CRUDE;
  • 12 [hp_X]/59mL POTASSIUM ALUM;
  • 6 [hp_X]/59mL POTASSIUM CARBONATE;
  • 6 [hp_X]/59mL POTASSIUM CHLORIDE;
  • 6 [hp_X]/59mL POTASSIUM SULFATE;
  • 4 [hp_C]/59mL SACCHAROMYCES CEREVISIAE RNA;
  • 12 [hp_X]/59mL SILICON DIOXIDE;
  • 6 [hp_X]/59mL SODIUM CHLORIDE;
  • 6 [hp_X]/59mL SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE


Administration Route(s): ORAL

Dosage Form(s): LIQUID

Pharmacy Class(es):
  • Calculi Dissolution Agent [EPC];
  • Increased Large Intestinal Motility [PE];
  • Increased Large Intestinal Motility [PE];
  • Increased Large Intestinal Motility [PE];
  • Inhibition Large Intestine Fluid/Electrolyte Absorption [PE];
  • Inhibition Large Intestine Fluid/Electrolyte Absorption [PE];
  • Inhibition Large Intestine Fluid/Electrolyte Absorption [PE];
  • Inhibition Small Intestine Fluid/Electrolyte Absorption [PE];
  • Magnesium Ion Exchange Activity [MoA];
  • Osmotic Activity [MoA];
  • Osmotic Activity [MoA];
  • Osmotic Activity [MoA];
  • Osmotic Laxative [EPC];
  • Osmotic Laxative [EPC];
  • Osmotic Laxative [EPC];
  • Potassium Compounds [CS];
  • Potassium Compounds [CS];
  • Potassium Salt [EPC];
  • Potassium Salt [EPC];
  • Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]

Labeler Information

Labeler Name: OHM PHARMA INC.
Product Type: HUMAN OTC DRUG
FDA Application Number:
Marketing Category: UNAPPROVED HOMEOPATHIC
Start Marketing Date:11/20/2017

Package Information

No. Package Code Package Description Billing Unit
166096-722-0559 mL in 1 BOTTLE, DROPPER (66096-722-05)

NDC Record

Field Name Field Value Definition
PRODUCT NDC66096-722The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN OTC DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMELyme Disease Support 1The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEAlumen, Calcarea carbonica, DNA, Ferrum phosphoricum, Hepar sulphuris calcareum, Kali carbonicum, Kali muriaticum, Kali sulphuricum, Magnesia phosphorica, Natrum muriaticum, Natrum phosphoricum, RNA, Silicea.The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMELIQUIDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE11/20/2017This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEUNAPPROVED HOMEOPATHICProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
LABELER NAMEOHM PHARMA INC.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMECALCIUM SULFIDE; FERROSOFERRIC PHOSPHATE; HERRING SPERM DNA; MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE; OYSTER SHELL CALCIUM CARBONATE, CRUDE; POTASSIUM ALUM; POTASSIUM CARBONATE; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SACCHAROMYCES CEREVISIAE RNA; SILICON DIOXIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATEAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH6; 6; 4; 6; 6; 12; 6; 6; 6; 4; 12; 6; 6 
ACTIVE INGRED UNIT[hp_X]/59mL; [hp_X]/59mL; [hp_C]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_C]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL 
PHARM CLASSESCalculi Dissolution Agent [EPC], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Small Intestine Fluid/Electrolyte Absorption [PE], Magnesium Ion Exchange Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Potassium Compounds [CS], Potassium Compounds [CS], Potassium Salt [EPC], Potassium Salt [EPC], Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/1/2023